Targeting a specific protein in ovarian cancer treatment
Targeting B7-H3 in ovarian cancer
This study is testing a new way to treat ovarian cancer by using a special therapy that helps your own immune cells fight the cancer more effectively, and it's designed for patients who are looking for better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11009563 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for ovarian cancer using a type of immunotherapy called CAR-T cell therapy. The approach involves engineering patients' own T cells to target a protein known as B7-H3, which is found in high levels on ovarian cancer cells. The study aims to assess the safety and effectiveness of these modified T cells when administered directly into the abdominal cavity of patients. By addressing challenges such as the immunosuppressive environment of ovarian tumors, this research seeks to improve treatment outcomes for patients with this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer who have not responded to standard treatments.
Not a fit: Patients with early-stage ovarian cancer or those whose tumors do not express the B7-H3 protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with ovarian cancer.
How similar studies have performed: Previous research has shown promising results with CAR-T therapies in other cancers, indicating potential for success in this novel application.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Dotti, Gianpietro — Univ of North Carolina Chapel Hill
- Study coordinator: Dotti, Gianpietro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.